10Y UST5.31%+0.57%30Y MTG7.28%+3.56%SOFR3.90%+0.26%VNQ$89.93+0.87%XLRE$41.10+1.06%FED FUNDS3.88%
Real Estate Trail
Institutional Press Wire
PR Newswire · Office

AmyriAD Therapeutics Acquires Recognify Life Sciences, Expanding Its Clinical-Stage Cognition Pipeline with RL-007 (Inidascamine)

Via PR Newswire · October 7, 2026
Compiled by Real Estate Trail Editorial · October 7, 2026

Why this matters

Office continues to trade in two distinct markets: trophy assets in walkable submarkets that are leasing at or near record rents, and commodity Class B and C buildings where the basis is still resetting. Underwriting on the latter has moved toward replacement-cost-minus, with credit underwriting now leaning on tenant covenant and remaining lease term rather than mark-to-market expectations. For LP-positioned capital, the read-through is that the bifurcation is now a structural feature of the sector, not a cycle to wait out.

Editorial analysis · Real Estate Trail Editorial

On the RET wire

Computed from Real Estate Trail’s own tracked coverage

Excerpt from PR Newswire:
All-share transaction: Recognify shareholders – including atai Life Sciences, Catalio Capital Management and Sudhoff Family Office – become shareholders of AmyriAD RL-007 adds a differentiated clinical-stage cognition…
Read the full article at PR Newswire →

External link. Real Estate Trail does not republish source content.

Related coverage — Office

Commercial Observer · Office

John Meko of WiredScore: 5 Questions

WiredScore ’s latest report, “ Fit for lease: How digital connectivity became the new test for Class A offices ,” finds that 81 percent of tenants would choose an office suite with connectivity already installed over…

47m ago